Neurofibromatoses Type II - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neurofibromatoses Type II - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Neurofibromatoses Type II - Pipeline Review, H2 2015', provides an overview of the Neurofibromatoses Type II's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neurofibromatoses Type II and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neurofibromatoses Type II products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neurofibromatoses Type II pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type II
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type II pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Neurofibromatoses Type II Overview 6
Therapeutics Development 7
Pipeline Products for Neurofibromatoses Type II - Overview 7
Pipeline Products for Neurofibromatoses Type II - Comparative Analysis 8
Neurofibromatoses Type II - Therapeutics under Development by Companies 9
Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes 10
Neurofibromatoses Type II - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Neurofibromatoses Type II - Products under Development by Companies 13
Neurofibromatoses Type II - Products under Investigation by Universities/Institutes 14
Neurofibromatoses Type II - Companies Involved in Therapeutics Development 15
Arno Therapeutics, Inc. 15
CalAsia Pharmaceuticals, Inc. 16
Lixte Biotechnology Holdings, Inc. 17
Nexgenix Pharmaceuticals, LLC 18
Novartis AG 19
Neurofibromatoses Type II - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
AR-42 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
everolimus - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
FRAX-597 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LB-201 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LB-205 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NXD-30001 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Neurofibromatoses Type II - Recent Pipeline Updates 42
Neurofibromatoses Type II - Dormant Projects 48
Neurofibromatoses Type II - Product Development Milestones 49
Featured News & Press Releases 49
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables

Number of Products under Development for Neurofibromatoses Type II, H2 2015 7
Number of Products under Development for Neurofibromatoses Type II - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Neurofibromatoses Type II - Pipeline by Arno Therapeutics, Inc., H2 2015 15
Neurofibromatoses Type II - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015 16
Neurofibromatoses Type II - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 17
Neurofibromatoses Type II - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2015 18
Neurofibromatoses Type II - Pipeline by Novartis AG, H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 27
Neurofibromatoses Type II Therapeutics - Recent Pipeline Updates, H2 2015 42
Neurofibromatoses Type II - Dormant Projects, H2 2015 48